Proteros is a global market leader for protein X-ray crystallography drug discovery services with a mission to deliver substantial, high-quality scientific contributions to deciphering the mode-of-action analysis of challenging drug discovery targets on behalf of its clients. In addition to the company’s off-the-shelf research tools that offer established Gallery Structures, Proteins and Assays, Proteros has a respected track record of delivering customized Gene-to-Protein/Structure projects.
Proteros has also expanded its integrated drug discovery services by adding fragment/small molecules libraries and a series of biophysical screening and profiling technologies to its service portfolio and capabilities. Proteros has worked on more than 250 different targets supporting more than 100 drug discovery projects during the last three years and delivers more than 450 structures annually , including apo-structures, small molecule based protein ligand structures and Fab-Antigen structures based on protein X-ray crystallography.
As founding sponsor of the IBA conference, we are very excited to launch our cryo-EM drug discovery services aimed at deciphering complex and challenging structural biology targets, which are not accessible by X-ray crystallography.